Efficacy and Safety of Sofosbuvir Plus Daclatasvir with or without Ribavirin in Treatment of Egyptian Patients Infected with Chronic HCV (Single Centre Study)

Abstract

The current study was designed to describe the efficacy and safety of Sofosbuvir plus Daclatasvir with or without Ribavirin in treatment of chronic HCV in a cohort of Egyptian patients who were referred to the viral hepatitis unit in El -Fayoum general hospital. To fulfill such purpose, we studied 200 chronic HCV patients distributed on two groups of treatment regimen group I received Sofosbuvir plus Daclatasvir without Ribavirin; group II received Sofosbuvir plus Daclatasvir with Ribavirin. All patients were subjected before treatment to detailed history taking, clinical examination, radiological assessment with abdominal ultrasonography and laboratory investigations including: HCV RNA assay by PCR, liver profile tests, complete blood picture, creatinine, INR, alpha-fetoprotein, fasting blood sugar and HbA1c for diabetics. Some patients were subjected to abdominal CT with contrast if hepatic focal lesions were detected by abdominal ultrasonography or if there was marked elevation of alpha-fetoprotein, while patients > 65 years were subjected to echocardiography.